It has been observed for many years, in many studies, that ALK+ ALCL has characteristically low expression levels of B-cell Lymphoma 2 (BCL2) proteins [36,37,38], whereas BCL2 overexpression is a classical feature of cancers, including hematopoietic tumors. Here, BCL2 is linked to hematopoietic and lymphoid system neoplasm.